Substance P (SP), a member of the tachykinin family of neuropeptides, can immunomodulate human T cells and monocytes. SP has been shown to stimulate human monocytes to produce inflammatory cytokines and superoxide ions, and it enhances tumoricidal activity in vitro. A specific SP receptor, however, has not been identified on human monocytes/macrophages. In this study, we report that '251-SP binds to human monocytes/macrophages with high affinity and specificity (Kd = 2.7 x 10-8 to 5.5 x 10-8 M). Our measurements of binding affinity to this single class of receptors were possible only when experiments were performed in the presence of excess serine proteinase inhibitor (serpin) enzyme complex receptor ligand. We determined that 1251-SP bound to a specific receptor on human monocytes/macrophages and that this binding was detectable as early as 6 h and was maintained throughout 6 to 8 weeks in culture. Modulation of the diverse immunological and inflammatory effects of SP on human monocytes may be mediated through this specific SP receptor.
immune system, SP interactions with lymphocytes have been well characterized (12, 27, 28) . SP has been shown to be a human T-cell mitogen and to augment the stimulatory effects of specific mitogens (27) . Flow cytometric analysis has been used to demonstrate the binding of SP to subpopulations of both suppressor and helper T lymphocytes (28) . SP enhances immunoglobulin production from cloned B lymphoma cells and has been shown to bind with high affinity and specificity to IM-9 human B-lymphoblast cells in vitro (25, 26) . In addition to the numerous effects SP has on lymphocytes, SP has been shown to elicit a wide variety of responses from human monocytes/macrophages (17, 29, 34) .
Stimulation of human monocytes by SP results in production of inflammatory cytokines such as interleukin-1 (IL-1), IL-6, and tumor necrosis factor alpha (16, 17) , enhanced superoxide ion production, and macrophage antitumor cytotoxicity (29) as well as monocyte chemotaxis (34, 35) . Recently, SP has been shown to maintain human bone marrow hematopoiesis in vitro. The authors hypothesized that adherent stromal cells, which may be macrophages, are involved in this process via the interaction of SP with a specific SP receptor (33) . Because many of the effects of SP on human monocytes/macrophages can be blocked with specific antagonists of SP, McGillis et al. proposed that human monocytes may express a specific receptor for SP (22) .
In rodent model systems, brain microglia and tissue macrophages have been reported to express SP receptors. Two classes of SP receptors have been detected on rat microglia 4% of SP receptors, while 96% of the receptors exhibit low-affinity binding of SP (Kd = 2.1 X 10-6 M) (20) . Guinea pig peritoneal macrophages release arachadonic acid metabolites and oxygen radicals in response to SP and have been shown to express a single class of high-affinity SP receptors with a Kd of 1.8 x 10-8 M (8, 9) . Additionally, while specific binding of SP to the murine macrophage cell line P338D1 has not been measured, studies demonstrate that these cells not only are responsive to the neuropeptide at low concentrations but also produce SP (14, 24) .
In this report, we demonstrate that human peripheral blood monocytes/macrophages express specific receptors for SP. We show that SP binding is detectable on human monocytes as early as 6 h after isolation and throughout 8 weeks in culture. However, determination of the affinity for SP binding to a single class of receptors was possible only when alpha-1-antitrypsin-trypsin (alpha-1-AT-T) complexes were included in binding assays. These findings are consistent with reports that human monocytes express a serine proteinase inhibitor (serpin) enzyme complex (SEC) receptor (30) . The SEC receptor can bind multiple ligands, including alpha-1-AT-T, alpha 1-antitrypsin-elastase, anti-thrombin II-thrombin, and alpha-1-antichymotrypsin-cathepsin G, and may facilitate clearance of such complexes (30) . Although the ligands that bind to the SEC receptor with high affinity are proteinase inhibitor enzyme complexes, SP has also been shown to interact with these receptors. At high concentrations, SP blocks specific binding of an alpha-1-antitrypsin peptide to the SEC receptor (13) . While SP can interact with the SEC receptor, authentic SEC ligands such as alpha-1-AT-T complexes do not bind to SP receptors (13) . This lack of SEC ligand binding to SP receptors made it possible for us to determine the binding affinity of a specific SP receptor. To make this determination of SP binding to a specific SP receptor, it was also necessary to account for the role of SP binding to the SEC receptor on monocytes/macrophages. This report is the initial characterization of high-affinity binding of SP to a specific receptor on human monocytes/ macrophages. Future studies will determine whether the highaffinity receptor characterized here is a member of the welldescribed family of neurokinin receptors and is responsible for mediating the multitude of effects of SP on human monocytes/ Preparation of alpha-l-AT-T complexes. Lyophilized alpha-1-AT was reconstituted in 300 mM sodium phosphate buffer (pH 6.5) to a concentration of 20 mg/ml. Trypsin type XIII was prepared as a 20-mg/ml stock solution in deionized water immediately before use. Alpha-1-AT-T complexes were prepared by the procedure described by Perlmutter et al. (31) with modifications. Equimolar amounts of trypsin and alpha-i-AT were combined at 37°C for 20 min. The incubation was stopped by the addition of phenylmethylsulfonyl fluoride to a final concentration of 2 mM, and an aliquot was removed for native polyacrylamide gel electrophoresis (PAGE) analysis. The formation of alpha-1-AT-T complexes was monitored by a mobility shift on nondenaturing PAGE. Polyacrylamide Phast gels (8 to 25% gradient) were obtained from Pharmacia LKB Biotechnology (Piscataway, N.J.). Aliquots of alpha-i-AT and alpha-1-AT-T complexes were applied to the (Phast) gels and run for an average of 125 V -h as described in the manufacturer's guidelines (Pharmacia Phast System). Alpha-i-AT and alpha-1-AT-T complexes were visualized after the gels were stained with Coomassie brilliant blue R-250. The final stock solution of alpha-1-AT-T complexes (1.7 x 10-4 M) was stored at 4°C. (i) Equilibrium binding assays. Monocytes/macrophages cultured in four-well plates were assayed for specific binding of "2I-SP after 21 days in culture. On the day of assay, plates were removed from the 37°C incubator and placed on ice, and the culture medium was replaced with 1.0 ml of ice-cold HMEM-HEPES binding medium. The cells were incubated on ice for 10 min. The HMEM-HEPES binding medium was replaced with 300 ,ul of HMEM-HEPES binding medium containing 0.125 nM 125I-SP, and incubation on ice continued.
Background binding was determined in parallel wells containing both 0.125 nM 1"I-SP and 1.0 x 10-4 M unlabelled SP. At the times indicated, HMEM-HEPES binding media were removed, and the cells were washed five times with ice-cold Hanks' balanced salt solution. Cells were solubilized in 1 (for 4-well plates) or 0.5 (for 48-well plates) ml of 0.1% sodium dodecyl sulfate (SDS), the radioactivity per well was determined, and protein assays were performed.
( in which alpha-1-AT-T complexes were included, 500-foldexcess complex, relative to the 1251-SP concentration, was added to the 1251-SP stock solutions before serial dilutions were performed. On the day of assay, plates were removed from the 37°C incubator and placed on ice. The culture medium was immediately replaced with 0.5 ml of ice-cold HMEM-HEPES binding medium, and the cells were incubated for 30 min on ice. The HMEM-HEPES binding medium was replaced with 125 ,ul of the ice-cold HMEM-HEPES binding medium containing l25I-SP at concentrations ranging from 0.15 x 10-9 M to 100 x 10-9 M. Background binding determinations were performed in parallel wells by adding at least 10-4 M unlabelled SP. After 90 min, the 125I-SP-containing media were removed, and the cells were washed four times with 1.0 ml of ice-cold Hanks' balanced salt solution (pH 7.4). The cell monolayers were solubilized in 0.5 ml of 0.1% SDS, the radioactivity per well was determined, and protein assays were performed.
RESULTS
Specific binding of SP to human monocytes/macrophages has not been described previously. To determine the kinetics of '25I-SP binding to human monocytes/macrophages at 4°C, equilibrium binding experiments were performed. Monocytes/ macrophages cultured for 3 weeks in four-well plates were assayed for specific 1251-SP binding over a 120-min time course (Fig. 1) eral blood monocytes and mature macrophages (37, 38, 40) . Transferrin receptors, however, are not detectable on peripheral blood monocytes until after 3 days in culture, with maximum expression observed only after 10 to 14 days in culture (11) .
To determine when human peripheral blood monocytes exhibit specific binding for SP and to determine the level and longevity of surface receptor expression, 125I-SP binding was performed on cells isolated from normal donors. Experiments were performed on the indicated days throughout a 6-to 8-week time course (Fig. 2) . As shown in Fig. 2A To address whether the specific binding of 1251-SP on cells presented in Fig. 2A was representative of normal donors, human peripheral blood monocytes/macrophages were isolated and cultured from three additional donors. Because cells from all four donors were obtained within a 3-week period, the same lot of 1251-SP ligand was used to determine specific binding. As presented in Fig. 2B , the amounts of specific 125I-SP binding to cells from these three donors were similar to that measured for the first donor ( Fig. 2A) . Interestingly, cells from three of four donors exhibited an early initial decrease in specific binding. The reason for this decrease is not known; however, binding was specific (less than 15% background binding) on each day that assays were performed. The overall decline in specific binding observed late in the time course may represent a one-half-life decay in the specific activity of the 25I-SP ligand. Each day that assays were done, microscopic observation of the cell cultures was also performed to rule out loss of cells. Only these four donors were studied over the 6-week time course. Attempts were made to assay human peripheral blood monocytes at an even earlier time than that presented in Fig.   2 . On the day leukopak cells were received from donors 1, 3, and 4, aliquots of buffy coat cells were adhered twice for two sequential 2-h intervals and then assayed for specific binding (approximately 6 h after isolation). In these samples, binding was two to three times greater than that measured on day 1 (12, 850, 20, 475 (13) . Therefore, to eliminate SP binding to this' second class of receptors, we prepared alpha-1-AT-T complexes and repeated the experiments described above in the presence of excess amounts of this SEC receptor ligand.
The SEC receptor ligands, alpha-1-AT-T complexes, were prepared as described in Materials and Methods. The successful formation of the complexes was demonstrated prior to use by nondenaturing PAGE analysis (Fig. 3) . Alpha-i-AT before the incubation with trypsin is shown in lane 1. The band in lane 2 represents alpha-1-AT-T complex and demonstrates the reduced mobility of alpha-i-AT after binding trypsin.
125I-SP binding experiments were performed in the presence of 500-fold-excess alpha-1-AT-T complexes relative to the 1251-SP concentration used. The concentrations of 1251-SP used ranged from 0.15 X 10-9 M to 100 x 10-9 M. Under these conditions, 125I-SP binding was again found to be specific and saturable (Fig. 4A) . However, unlike those for binding performed in the absence of excess alpha-1-AT-T complexes, these data could be transformed into a linear plot by Scatchard analysis (Fig. 4B) . The binding constant, Kd, was determined to be 2. 
DISCUSSION
Human monocyte/macrophage membrane receptors modulate diverse biological responses, including activation, chemotaxis, and enzyme secretion (4). These cellular functions are part of a broad range of physiologic and pathologic processes, including inflammation, immune responsiveness, and tissue repair. Increasing evidence has shown that SP can elicit many of these monocyte/macrophage responses (17, 29, 34) , and yet, to date, no specific SP receptor has been identified on these human cells. This is the first report that SP can bind with high affinity and specificity to human peripheral blood monocytes/ macrophages.
Our initial attempts to measure the affinity of 1251-SP binding to monocytes/macrophages yielded complex binding isotherms. Soon after we performed these experiments, a report by Joslin et al. (13) (10) and lower than the binding affinity we determined as shown in Fig. 4 . Thus, the 1251-SP concentration used (0.875 x 10-9 M) was expected to occupy less than 10% of the high-affinity SP receptors at equilibrium, with virtually no binding to the SEC receptor. In fact, attempts to compete for '25I-SP binding to macrophages with alpha-i-AT-T complexes at these low concentrations of 125I-SP resulted in no reduction of SP binding (data not shown), supporting the postulate that SP binds with lower affinity to the SEC receptor.
We estimated that the number of specific SP binding sites on human monocytes/macrophages was approximately 70,000 per cell, more than the number on human T cells, which are reported to express approximately 7,000 receptors per cell (28) . Isolation and further analysis of the SP receptor expressed on human monocytes/macrophages will be required to determine whether it is identical to the SP receptor (NK-1 or neurokinin 1 receptor) found on other cells (10) or a novel SP receptor.
Payan et al. noted that short-term (1-to 2-h) adherencepurified monocytes from two donors lacked SP receptors as determined by flow cytometry using a fluorescein-labelled SP probe and in binding experiments utilizing 3H-SP as a ligand (28) . The disparity between their observations and ours is most likely due to differences in methodologies and monocyte isolation and culture conditions. We found SP binding to monocytes/macrophages throughout the 6 to 8 weeks in culture for all four donors tested, with variability in binding as shown in Fig. 2 . Lipopolysaccharide (LPS) contamination of reagents was not directly tested, but we doubt that LPS could account for the consistent SP binding to monocytes/macrophages. The commercial source of fetal bovine serum used in these studies was specifically chosen because it is screened for LPS.
SP interaction with monocytes results in the production of inflammatory cytokines such as IL-1, IL-6, and tumor necrosis factor alpha (16, 17) . Martin et al. have proposed that production of these three cytokines could contribute to neurologic inflammatory diseases such as multiple sclerosis (20, 21) . Additionally, in vitro and animal model experiments have shown that SP may counteract the neurotoxic effects of the 3-amyloid protein associated with the neurodegenerative effects of Alzheimer's disease (15, 39) .
SP has also been reported to block in vitro replication of the measles paramyxovirus (36) . The carboxyl terminus of SP is homologous to the fusion domain of the measles virus fusion protein (FI) (6) . Thus, SP has been postulated to interfere with the fusion step of viral entry (36) and the SP receptor itself to facilitate the fusion process of measles virus with its target cells (6, 7) . Since the fusion domain of paramyxoviruses such as measles shares homologies not only with SP but with the fusion domain in the gp4l envelope protein of human immunodeficiency virus type 1 (1, 3) , then the SP receptor may facilitate the fusion process of viral entry into monocytes/macrophages for both measles and human immunodeficiency virus type 1.
SP stimulation of human monocytes/macrophages may be important in infectious, inflammatory, and neurodegenerative diseases. Therefore, defining the role of SP receptors in mediating monocyte/macrophage function will contribute to our understanding of diverse disease processes.
